FBRX Forte Biosciences, Inc.
Price Chart
Executive Summary
Forte Biosciences filed a universal shelf registration statement on Form S-3 to offer and sell up to $500,000,000 in securities (common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts, and units) from time to time. The company has a market cap of $342M, meaning the shelf represents ~146% of current market cap, signaling massive potential dilution. The filing is a placeholder — no specific offering is announced — but the company's cash burn is accelerating (Q1 2026 net loss of $22.1M vs $15.7M a year ago), and cash & equivalents fell from $77.0M to $58.2M in Q1 2026, suggesting the company will likely tap this shelf soon to fund operations.
Key Financial Metrics
Actionable Insight
The shelf filing itself is not an immediate dilutive event, but the accelerating cash burn ($22M quarterly loss) and declining cash position ($58.2M) make it highly likely the company will tap this shelf soon. Monitor for a prospectus supplement announcing a specific offering — that will be the actual dilutive event. The 91% analyst bullishness is at odds with the deteriorating cash position; expect downward estimate revisions if a dilutive offering materializes.
Key Facts
- Shelf registration for up to $500,000,000 in securities — ~146% of current $342M market cap
- Cash & equivalents declined from $77.0M (Dec 2025) to $58.2M (Mar 2026)
- Q1 2026 net loss of $22.1M vs $15.7M in Q1 2025 — burn rate accelerating
- Operating expenses rose 39% YoY to $22.4M, driven by R&D spend of $20.3M
- Accumulated deficit grew to $245.5M as of March 31, 2026
- No specific offering announced — shelf is a forward-looking capital-raising mechanism
- Company is a clinical-stage biopharma with no approved products or revenue
- Prior shelf (File No. 333-286226) had $50.7M in unsold securities carried forward into this filing
Financial Impact
Shelf of $500M represents ~146% dilution vs current $342M market cap; cash burn of ~$22M/quarter implies ~2.6 quarters of runway at current cash level of $58.2M
Risk Factors
- Massive potential dilution — shelf is 146% of current market cap
- Accelerating cash burn with no approved products or revenue
- Clinical-stage biotech with binary pipeline risk (Phase 2 celiac data expected 2026)
- Prior shelf carry-forward of $50.7M suggests previous capital raises were insufficient
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-253668 |
| Document: d117004dex43.htm | 0001193125-26-253668 |
| Document: d117004dexfilingfees.htm | 0001193125-26-253668 |
| Document: d117004dex51.htm | 0001193125-26-253668 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
4d ago
|
EFFECT
| $16.86 awaiting T+1 | awaiting T+1 | — | $17.56 (−4.15%) |
|
Jun 6, 2026
9d ago
|
S-3/A
| $16.37 awaiting T+1 | awaiting T+1 | — | $17.56 (−7.27%) |
|
Jun 2, 2026
12d ago
|
S-3
| $17.00 $16.69 | ▲ +1.82% | ▲ +2.22% | $17.56 (−3.29%) |
|
Jun 2, 2026
12d ago
|
8-K
| $17.00 $16.69 | ▼ −1.82% | ▼ −2.23% | $17.56 (+3.29%) |
|
May 14, 2026
4w ago
|
8-K
| $23.11 $20.97 | ▼ −9.26% | ▼ −9.20% | $17.56 (−24.02%) |
|
Apr 9, 2026
9w ago
|
8-K
| $33.90 $35.09 | ▲ +3.51% | ▲ +3.57% | $17.56 (−48.20%) |
|
Apr 8, 2026
9w ago
|
424B5
| $33.90 $35.09 | ▼ −3.51% | ▼ −3.57% | $17.56 (+48.20%) |
|
Apr 1, 2026
10w ago
|
8-K
| $24.86 $25.58 | ▼ −2.90% | ▼ −2.82% | $17.56 (+29.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access